SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MJ who wrote (1113)12/18/2005 11:55:03 PM
From: tuck  Read Replies (1) of 1154
 
Never mind, brain failure there. I was thinking that was FACTIVE; obviously I haven't been paying close enough attention to OSCI recently. Since Ramoplanin isn't approved yet, it's a little premature to talk about off-label uses. In fact, it's been trialed for CDAD (PII, I think), with the idea of going after vancomycin-resistant strains, and so this in vitro data isn't exactly earth shattering news. Apologies if you already knew all this.

In any case, to answer your question, a drug is approved for a specific indication, and this is specified on its label. When data is available that supports its use in another indication, doctors might prescribe it for that latter indication if the efficacy versus side effect profile seems appropriate.

Celgene's Thalomid is the perhaps the poster child of off label use. Approved for a rare disorder, it has been wildly successful off-label in treating certain other blood cancers.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News